Swot Analysis of "ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter" written by Josh Lerner includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Gefter Immulogic facing as an external strategic factors. Some of the topics covered in ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter case study are - Strategic Management Strategies, Entrepreneurial management, Financial analysis, Financial management, Financial markets and Finance & Accounting.
Some of the macro environment factors that can be used to understand the ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter casestudy better are - – supply chains are disrupted by pandemic , increasing transportation and logistics costs, increasing inequality as vast percentage of new income is going to the top 1%, cloud computing is disrupting traditional business models, increasing government debt because of Covid-19 spendings, technology disruption, challanges to central banks by blockchain based private currencies,
geopolitical disruptions, wage bills are increasing, etc
Introduction to SWOT Analysis of ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Gefter Immulogic, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Gefter Immulogic operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter can be done for the following purposes –
1. Strategic planning using facts provided in ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter case study
2. Improving business portfolio management of Gefter Immulogic
3. Assessing feasibility of the new initiative in Finance & Accounting field.
4. Making a Finance & Accounting topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Gefter Immulogic
Strengths ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Gefter Immulogic in ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter Harvard Business Review case study are -
High brand equity
– Gefter Immulogic has strong brand awareness and brand recognition among both - the exiting customers and potential new customers. Strong brand equity has enabled Gefter Immulogic to keep acquiring new customers and building profitable relationship with both the new and loyal customers.
Highly skilled collaborators
– Gefter Immulogic has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive segment. Secondly the value chain collaborators of the firm in ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter HBR case study have helped the firm to develop new products and bring them quickly to the marketplace.
Analytics focus
– Gefter Immulogic is putting a lot of focus on utilizing the power of analytics in business decision making. This has put it among the leading players in the industry. The technology infrastructure suggested by Josh Lerner can also help it to harness the power of analytics for – marketing optimization, demand forecasting, customer relationship management, inventory management, information sharing across the value chain etc.
Low bargaining power of suppliers
– Suppliers of Gefter Immulogic in the sector have low bargaining power. ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter has further diversified its suppliers portfolio by building a robust supply chain across various countries. This helps Gefter Immulogic to manage not only supply disruptions but also source products at highly competitive prices.
Superior customer experience
– The customer experience strategy of Gefter Immulogic in the segment is based on four key concepts – personalization, simplification of complex needs, prompt response, and continuous engagement.
Organizational Resilience of Gefter Immulogic
– The covid-19 pandemic has put organizational resilience at the centre of everthing that Gefter Immulogic does. Organizational resilience comprises - Financial Resilience, Operational Resilience, Technological Resilience, Organizational Resilience, Business Model Resilience, and Reputation Resilience.
Effective Research and Development (R&D)
– Gefter Immulogic has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in, as mentioned in case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter - staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
Digital Transformation in Finance & Accounting segment
- digital transformation varies from industry to industry. For Gefter Immulogic digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Gefter Immulogic has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Training and development
– Gefter Immulogic has one of the best training and development program in the industry. The effectiveness of the training programs can be measured in ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter Harvard Business Review case study by analyzing – employees retention, in-house promotion, loyalty, new venture initiation, lack of conflict, and high level of both employees and customer engagement.
Sustainable margins compare to other players in Finance & Accounting industry
– ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter firm has clearly differentiated products in the market place. This has enabled Gefter Immulogic to fetch slight price premium compare to the competitors in the Finance & Accounting industry. The sustainable margins have also helped Gefter Immulogic to invest into research and development (R&D) and innovation.
Learning organization
- Gefter Immulogic is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Gefter Immulogic is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders in ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter Harvard Business Review case study emphasize – knowledge, initiative, and innovation.
Ability to recruit top talent
– Gefter Immulogic is one of the leading recruiters in the industry. Managers in the ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter are in a position to attract the best talent available. The firm has a robust talent identification program that helps in identifying the brightest.
Weaknesses ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter are -
Increasing silos among functional specialists
– The organizational structure of Gefter Immulogic is dominated by functional specialists. It is not different from other players in the Finance & Accounting segment. Gefter Immulogic needs to de-silo the office environment to harness the true potential of its workforce. Secondly the de-silo will also help Gefter Immulogic to focus more on services rather than just following the product oriented approach.
Slow to harness new channels of communication
– Even though competitors are using new communication channels such as Instagram, Tiktok, and Snap, Gefter Immulogic is slow explore the new channels of communication. These new channels of communication mentioned in marketing section of case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter can help to provide better information regarding products and services. It can also build an online community to further reach out to potential customers.
No frontier risks strategy
– After analyzing the HBR case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter, it seems that company is thinking about the frontier risks that can impact Finance & Accounting strategy. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
Need for greater diversity
– Gefter Immulogic has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
Products dominated business model
– Even though Gefter Immulogic has some of the most successful products in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. firm in the HBR case study - ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter should strive to include more intangible value offerings along with its core products and services.
High dependence on star products
– The top 2 products and services of the firm as mentioned in the ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter HBR case study still accounts for major business revenue. This dependence on star products in has resulted into insufficient focus on developing new products, even though Gefter Immulogic has relatively successful track record of launching new products.
High operating costs
– Compare to the competitors, firm in the HBR case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter has high operating costs in the. This can be harder to sustain given the new emerging competition from nimble players who are using technology to attract Gefter Immulogic 's lucrative customers.
Lack of clear differentiation of Gefter Immulogic products
– To increase the profitability and margins on the products, Gefter Immulogic needs to provide more differentiated products than what it is currently offering in the marketplace.
Compensation and incentives
– The revenue per employee as mentioned in the HBR case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter, is just above the industry average. Gefter Immulogic needs to redesign the compensation structure and incentives to increase the revenue per employees. Some of the steps that it can take are – hiring more specialists on project basis, etc.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Gefter Immulogic supply chain. Even after few cautionary changes mentioned in the HBR case study - ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter, it is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Gefter Immulogic vulnerable to further global disruptions in South East Asia.
Interest costs
– Compare to the competition, Gefter Immulogic has borrowed money from the capital market at higher rates. It needs to restructure the interest payment and costs so that it can compete better and improve profitability.
Opportunities ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter are -
Buying journey improvements
– Gefter Immulogic can improve the customer journey of consumers in the industry by using analytics and artificial intelligence. ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter suggest that firm can provide automated chats to help consumers solve their own problems, provide online suggestions to get maximum out of the products and services, and help consumers to build a community where they can interact with each other to develop new features and uses.
Finding new ways to collaborate
– Covid-19 has not only transformed business models of companies in Finance & Accounting industry, but it has also influenced the consumer preferences. Gefter Immulogic can tie-up with other value chain partners to explore new opportunities regarding meeting customer demands and building a rewarding and engaging relationship.
Loyalty marketing
– Gefter Immulogic has focused on building a highly responsive customer relationship management platform. This platform is built on in-house data and driven by analytics and artificial intelligence. The customer analytics can help the organization to fine tune its loyalty marketing efforts, increase the wallet share of the organization, reduce wastage on mainstream advertising spending, build better pricing strategies using personalization, etc.
Use of Bitcoin and other crypto currencies for transactions
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Gefter Immulogic in the consumer business. Now Gefter Immulogic can target international markets with far fewer capital restrictions requirements than the existing system.
Using analytics as competitive advantage
– Gefter Immulogic has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in the sector. This continuous investment in analytics has enabled, as illustrated in the Harvard case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter - to build a competitive advantage using analytics. The analytics driven competitive advantage can help Gefter Immulogic to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Creating value in data economy
– The success of analytics program of Gefter Immulogic has opened avenues for new revenue streams for the organization in the industry. This can help Gefter Immulogic to build a more holistic ecosystem as suggested in the ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter case study. Gefter Immulogic can build new products and services such as - data insight services, data privacy related products, data based consulting services, etc.
Building a culture of innovation
– managers at Gefter Immulogic can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the Finance & Accounting segment.
Reforming the budgeting process
- By establishing new metrics that will be used to evaluate both existing and potential projects Gefter Immulogic can not only reduce the costs of the project but also help it in integrating the projects with other processes within the organization.
Harnessing reconfiguration of the global supply chains
– As the trade war between US and China heats up in the coming years, Gefter Immulogic can build a diversified supply chain model across various countries in - South East Asia, India, and other parts of the world. This reconfiguration of global supply chain can help, as suggested in case study, ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter, to buy more products closer to the markets, and it can leverage its size and influence to get better deal from the local markets.
Reconfiguring business model
– The expansion of digital payment system, the bringing down of international transactions costs using Bitcoin and other blockchain based currencies, etc can help Gefter Immulogic to reconfigure its entire business model. For example it can used blockchain based technologies to reduce piracy of its products in the big markets such as China. Secondly it can use the popularity of e-commerce in various developing markets to build a Direct to Customer business model rather than the current Channel Heavy distribution network.
Lowering marketing communication costs
– 5G expansion will open new opportunities for Gefter Immulogic in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the Finance & Accounting segment, and it will provide faster access to the consumers.
Learning at scale
– Online learning technologies has now opened space for Gefter Immulogic to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Gefter Immulogic is facing challenges because of the dominance of functional experts in the organization. ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter case study suggests that firm can utilize new technology to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Threats ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter are -
Backlash against dominant players
– US Congress and other legislative arms of the government are getting tough on big business especially technology companies. The digital arm of Gefter Immulogic business can come under increasing regulations regarding data privacy, data security, etc.
High dependence on third party suppliers
– Gefter Immulogic high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Stagnating economy with rate increase
– Gefter Immulogic can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the field.
Instability in the European markets
– European Union markets are facing three big challenges post Covid – expanded balance sheets, Brexit related business disruption, and aggressive Russia looking to distract the existing security mechanism. Gefter Immulogic will face different problems in different parts of Europe. For example it will face inflationary pressures in UK, France, and Germany, balance sheet expansion and demand challenges in Southern European countries, and geopolitical instability in the Eastern Europe.
Learning curve for new practices
– As the technology based on artificial intelligence and machine learning platform is getting complex, as highlighted in case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter, Gefter Immulogic may face longer learning curve for training and development of existing employees. This can open space for more nimble competitors in the field of Finance & Accounting .
Increasing wage structure of Gefter Immulogic
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Gefter Immulogic.
Regulatory challenges
– Gefter Immulogic needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the Finance & Accounting industry regulations.
Trade war between China and United States
– The trade war between two of the biggest economies can hugely impact the opportunities for Gefter Immulogic in the Finance & Accounting industry. The Finance & Accounting industry is already at various protected from local competition in China, with the rise of trade war the protection levels may go up. This presents a clear threat of current business model in Chinese market.
Increasing international competition and downward pressure on margins
– Apart from technology driven competitive advantage dilution, Gefter Immulogic can face downward pressure on margins from increasing competition from international players. The international players have stable revenue in their home market and can use those resources to penetrate prominent markets illustrated in HBR case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter .
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Gefter Immulogic.
Easy access to finance
– Easy access to finance in Finance & Accounting field will also reduce the barriers to entry in the industry, thus putting downward pressure on the prices because of increasing competition. Gefter Immulogic can utilize it by borrowing at lower rates and invest it into research and development, capital expenditure to fortify its core competitive advantage.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Gefter Immulogic in the Finance & Accounting sector and impact the bottomline of the organization.
Weighted SWOT Analysis of ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of ImmuLogic Pharmaceutical Corp. (B1): Malcolm Gefter is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Gefter Immulogic needs to make to build a sustainable competitive advantage.